Vimarsana
Biggest News Aggregation in the World

Page 25 - Sciences Corp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sciences Corp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sciences Corp Today - Breaking & Trending Today

Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions - Cisco Systems (NASDAQ:CSCO), Exact Sciences (NASDAQ:EXAS), Recursion Pharmaceuticals (NASDAQ:RXRX), ARK Innovation ETF (ARCA:ARKK), Shopify (NYSE:SHOP), Archer Aviation (NYSE:ACHR), ARK Genomic Revolution ETF (BATS:ARKG), Tesla (NASDAQ:TSLA), Ginkgo Bioworks Holdings (NYSE:DNA), Wolfspeed (NYSE:WOLF), StoneCo (NASDAQ:STNE), Intellia Therapeutics (NASDAQ:NTLA), Walmart (NYSE:WMT) - Vimarsana News

Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions - Cisco Systems (NASDAQ:CSCO), Exact Sciences (NASDAQ:EXAS), Recursion Pharmaceuticals (NASDAQ:RXRX), ARK Innovation ETF (ARCA:ARKK), Shopify (NYSE:SHOP), Archer Aviation (NYSE:ACHR), ARK Genomic Revolution ETF (BATS:ARKG), Tesla (NASDAQ:TSLA), Ginkgo Bioworks Holdings (NYSE:DNA), Wolfspeed (NYSE:WOLF), StoneCo (NASDAQ:STNE), Intellia Therapeutics (NASDAQ:NTLA), Walmart (NYSE:WMT)

ASCO 2023: Solid Tumors - Vimarsana News

ASCO 2023: Solid Tumors

Coverage of clinical trial results presented across a range of solid tumor cancers, including breast, ovarian, colorectal, and non-small cell lung cancer, among other types; as well as important findings in genomic testing.

Source: ajmc.com
Exact Sciences' Q2 results beat analysts' expectations - Vimarsana News

Exact Sciences' Q2 results beat analysts' expectations

The biomedical giant best known for its Cologuard test reported a second-quarter loss of $81 million, or 45 cents per share, on revenue of $622.1 million.

Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth - Exact Sciences (NASDAQ:EXAS) - Vimarsana News

Exact Sciences Q2 Earnings Surpass Expectation, But Analyst Says Stock Has Limited Growth - Exact Sciences (NASDAQ:EXAS)

Exact Sciences Corp (NASDAQ: EXAS) reported Q2 revenue of $622 million, an increase of 19%, and $617 million of core revenue, an increase of 24%, beating the 

Exact Sciences Announces Second-Quarter 2023 Results - Vimarsana News

Exact Sciences Announces Second-Quarter 2023 Results

MADISON - Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June...